National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2026

Overview

The National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2026, also cited as PB 44 of 2026, was enacted to amend the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023. This determination aims to address the need for regulating the prices of specific pharmaceutical brands to ensure affordability and accessibility for consumers under the Pharmaceutical Benefits Scheme (PBS). The determination was made by Rebecca Richardson, as delegate of the Minister for Health, Disability and Ageing, under the authority of subsection 99ADHC(2) of the National Health Act 1953. The primary policy objective of this amendment is to introduce additional designated brands that will be subject to a floor price, effective from 1 October 2026. This will help maintain a consistent pricing structure for essential medications, ensuring that patients have reasonable access to necessary treatments.

Scope and Application

The National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2026 applies to specific pharmaceutical items and brands, amending the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023. The determination sets out a floor price for certain brands of pharmaceutical items, thereby regulating the pricing of these medications within the Australian healthcare system. The amendment pertains to additional designated brands, effective from 1 October 2026, and is applicable nationwide. The act applies to pharmaceutical entities and manufacturers that produce and supply the specified brands of pharmaceutical items listed in the amended determination. Through this legislative instrument, the Commonwealth aims to ensure affordable access to essential medications by setting a minimum price for the listed pharmaceutical brands. The scope of the amendment extends only to the brands listed in Schedule 1 and does not affect other pharmaceutical items not specified in the schedule. The application of this determination is subject to further specifications and regulations that may be established through subordinate instruments.

Key Provisions

The National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2026, effective from 1 October 2026, amends the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023. It introduces additional designated brands with a floor price for pharmaceutical items (sections 1 to 4). The specific brands added include Ruzurgi, Amifampridine, Essential Care Jr, APO-Atomoxetine, Atomoxetine Sandoz, Atropt, Akamin 50, Minomycin-50, Octreotide GH, Octreotide (SUN), Sandostatin 0.05, Sandostatin 0.1, Pegasys, Span-K, Chlorvescent, and DBL Vincristine Sulfate. These additions are detailed in Schedule 1, which amends Section 5 of the original determination by inserting new brands into the list of designated pharmaceutical items. The Act imposes several obligations on pharmaceutical companies and entities involved in the supply and pricing of these designated brands. These entities must adhere to the floor prices set for the listed pharmaceutical items, ensuring that they do not sell these items below the specified minimum prices. This requirement is crucial for maintaining equitable access to essential medications and preventing price competition that could lead to reduced availability or affordability of these drugs. Additionally, the entities are required to report any changes in pricing or supply that might affect the floor price regime. Failure to comply with the floor price requirements can result in significant consequences. The Act does not explicitly state the penalties for non-compliance, but breaches of similar provisions in related legislation typically result in financial penalties. These penalties can be substantial, often reflecting the seriousness of the breach and its impact on public health. Additionally, repeated or severe non-compliance might lead to further regulatory actions, including potential legal proceedings to enforce compliance or to seek damages for any harm caused by non-compliance. The Determination is made under the authority of the National Health Act 1953, specifically under subsection 99ADHC(2), which empowers the Minister for Health, Disability and Ageing to establish and enforce floor prices for pharmaceutical items. The amendments detailed in Schedule 1 are directly applied to the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023, modifying the list of designated brands and their associated floor prices.